Liraglutide and pioglitazone treatment in obese polycystic ovary syndrome and its impact on blood levels of chemerin and visfatin
Updated
Abstract
The evaluation focuses on liraglutide combined with pioglitazone in obese patients with polycystic ovary syndrome (PCOS).
- Liraglutide and pioglitazone may improve clinical efficacy and safety in treating obesity-related issues in PCOS patients.
- Serum chemerin and visfatin, along with their ratio, could serve as predictive markers for the improvement of insulin resistance.
- The study investigates the relationship between these biomarkers and insulin resistance in the context of PCOS.
Simplified
Funding
Competing interests
None.
PubMed